FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137071075> ?p ?o ?g. }

• W2137071075 endingPage "639" @default.
• W2137071075 startingPage "629" @default.
• W2137071075 abstract "Objective. Assess longterm tolerability, safety, and efficacy of subcutaneous (SC) abatacept (ABA) in methotrexate-refractory patients with rheumatoid arthritis (RA). Methods. The phase III, multinational Abatacept Comparison of Sub[QU]cutaneous Versus Intravenous in Inadequate Responders to MethotrexatE (ACQUIRE) trial comprised a 6-month, randomized, double-blind (DB) period, in which patients received intravenous (IV) or SC ABA, plus MTX, followed by an open-label, longterm extension (LTE), in which patients received SC ABA, 125 mg/week. Safety and efficacy from the LTE (∼3.5 yrs of exposure) are reported. Results. Patients who completed the DB period (1372/1385, 99.1%) entered the LTE; 1134 patients (82.7%) kept taking the treatment at time of reporting. Mean (SD) was 31.9 months (6.8); median (range) exposure was 33.0 (8–44) months. Patients entering the LTE had longstanding, moderate-to-severe disease [mean 7.6 (7.9) yrs and DAS28 (C-reactive protein) 6.2 (0.9)]. Incidence rates (events/100 patient-yrs) were reported for serious adverse events (8.76, 95% CI 7.71, 9.95), infections (44.80, 95% CI 41.76, 48.01), serious infections (1.72, 95% CI 1.30, 2.27), malignancies (1.19, 95% CI 0.86, 1.66), and autoimmune events (1.31, 95% CI 0.95, 1.79). Twenty-seven patients (2%) experienced injection-site reactions; all except 1 were mild. American College of Rheumatology 20, 50, and 70 responses achieved during the DB period were maintained through the LTE, and on Day 981 were 80.2% (95% CI 77.2, 83.2), 63.5% (95% CI 58.2, 68.9), and 39.5% (95% CI 34.0, 44.9) for patients who kept taking SC ABA, and 80.0% (95% CI 77.0, 83.0), 63.2% (95% CI 57.8, 68.7), and 39.2% (95% CI 33.7, 44.7) for those who switched from IV to SC ABA. Conclusion. These findings support SC ABA as a well-tolerated and efficacious longterm treatment for patients with RA and inadequate response to MTX ( ClinicalTrials.gov identifier NCT00559585 )." @default.
• W2137071075 created "2016-06-24" @default.
• W2137071075 creator A5000779664 @default.
• W2137071075 creator A5003819213 @default.
• W2137071075 creator A5006029574 @default.
• W2137071075 creator A5011826741 @default.
• W2137071075 creator A5024454450 @default.
• W2137071075 creator A5026356361 @default.
• W2137071075 creator A5028932803 @default.
• W2137071075 creator A5032707830 @default.
• W2137071075 creator A5042605633 @default.
• W2137071075 creator A5044212347 @default.
• W2137071075 creator A5059124438 @default.
• W2137071075 creator A5060526475 @default.
• W2137071075 creator A5074452337 @default.
• W2137071075 creator A5078727612 @default.
• W2137071075 creator A5083576726 @default.
• W2137071075 creator A5083930527 @default.
• W2137071075 date "2014-03-01" @default.
• W2137071075 modified "2023-10-01" @default.
• W2137071075 title "Subcutaneous Abatacept for the Treatment of Rheumatoid Arthritis: Longterm Data from the ACQUIRE Trial" @default.
• W2137071075 cites W1996389186 @default.
• W2137071075 cites W2027865190 @default.
• W2137071075 cites W2028514817 @default.
• W2137071075 cites W2039539571 @default.
• W2137071075 cites W2045085974 @default.
• W2137071075 cites W2078595150 @default.
• W2137071075 cites W2104861305 @default.
• W2137071075 cites W2112244531 @default.
• W2137071075 cites W2115018403 @default.
• W2137071075 cites W2118704147 @default.
• W2137071075 cites W2119601740 @default.
• W2137071075 cites W2126049604 @default.
• W2137071075 cites W2139323151 @default.
• W2137071075 cites W2143475422 @default.
• W2137071075 cites W2152350812 @default.
• W2137071075 cites W2152368246 @default.
• W2137071075 cites W2156140442 @default.
• W2137071075 cites W2160817248 @default.
• W2137071075 cites W2164427325 @default.
• W2137071075 doi "https://doi.org/10.3899/jrheum.130112" @default.
• W2137071075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24584926" @default.
• W2137071075 hasPublicationYear "2014" @default.
• W2137071075 type Work @default.
• W2137071075 sameAs 2137071075 @default.
• W2137071075 citedByCount "31" @default.
• W2137071075 countsByYear W21370710752014 @default.
• W2137071075 countsByYear W21370710752015 @default.
• W2137071075 countsByYear W21370710752016 @default.
• W2137071075 countsByYear W21370710752017 @default.
• W2137071075 countsByYear W21370710752018 @default.
• W2137071075 countsByYear W21370710752019 @default.
• W2137071075 countsByYear W21370710752020 @default.
• W2137071075 countsByYear W21370710752021 @default.
• W2137071075 countsByYear W21370710752022 @default.
• W2137071075 crossrefType "journal-article" @default.
• W2137071075 hasAuthorship W2137071075A5000779664 @default.
• W2137071075 hasAuthorship W2137071075A5003819213 @default.
• W2137071075 hasAuthorship W2137071075A5006029574 @default.
• W2137071075 hasAuthorship W2137071075A5011826741 @default.
• W2137071075 hasAuthorship W2137071075A5024454450 @default.
• W2137071075 hasAuthorship W2137071075A5026356361 @default.
• W2137071075 hasAuthorship W2137071075A5028932803 @default.
• W2137071075 hasAuthorship W2137071075A5032707830 @default.
• W2137071075 hasAuthorship W2137071075A5042605633 @default.
• W2137071075 hasAuthorship W2137071075A5044212347 @default.
• W2137071075 hasAuthorship W2137071075A5059124438 @default.
• W2137071075 hasAuthorship W2137071075A5060526475 @default.
• W2137071075 hasAuthorship W2137071075A5074452337 @default.
• W2137071075 hasAuthorship W2137071075A5078727612 @default.
• W2137071075 hasAuthorship W2137071075A5083576726 @default.
• W2137071075 hasAuthorship W2137071075A5083930527 @default.
• W2137071075 hasBestOaLocation W21370710751 @default.
• W2137071075 hasConcept C120665830 @default.
• W2137071075 hasConcept C121332964 @default.
• W2137071075 hasConcept C126322002 @default.
• W2137071075 hasConcept C141071460 @default.
• W2137071075 hasConcept C197934379 @default.
• W2137071075 hasConcept C198451711 @default.
• W2137071075 hasConcept C2777575956 @default.
• W2137071075 hasConcept C2778375690 @default.
• W2137071075 hasConcept C2779338263 @default.
• W2137071075 hasConcept C2779605438 @default.
• W2137071075 hasConcept C2780653079 @default.
• W2137071075 hasConcept C2781059491 @default.
• W2137071075 hasConcept C61511704 @default.
• W2137071075 hasConcept C71924100 @default.
• W2137071075 hasConcept C90924648 @default.
• W2137071075 hasConceptScore W2137071075C120665830 @default.
• W2137071075 hasConceptScore W2137071075C121332964 @default.
• W2137071075 hasConceptScore W2137071075C126322002 @default.
• W2137071075 hasConceptScore W2137071075C141071460 @default.
• W2137071075 hasConceptScore W2137071075C197934379 @default.
• W2137071075 hasConceptScore W2137071075C198451711 @default.
• W2137071075 hasConceptScore W2137071075C2777575956 @default.
• W2137071075 hasConceptScore W2137071075C2778375690 @default.
• W2137071075 hasConceptScore W2137071075C2779338263 @default.
• W2137071075 hasConceptScore W2137071075C2779605438 @default.

• next